Provided is an enema for rectal application, which can be used for treating inflammatory bowel disease or preventing the recurrent of inflammatory bowel disease and contains budesonide as an active ingredient. An enema for rectal application, which is characterized by containing budesonide as an active ingredient and being administered in such a manner that a single dose of 1.5 to 2.5 mg of budesonide can be taken twice a day for 6 weeks for treating inflammatory bowel disease or preventing the recurrent of inflammatory bowel disease； an enema for rectal application as mentioned above, wherein the dose of budesonide per one time is 2.0 mg； any one of the above-mentioned enemas for rectal application, which is administered for treating ulcerative colitis or Crohn's disease or preventing the recurrence of ulcerative colitis or Crohn's disease； and any one of the aforementioned enemas for rectal application, which is in the form of a foam or a liquid.
